•Novo Nordisk received European Commission marketing authorization for Wegovy pill (oral semaglutide 25 mg) as the first oral GLP-1 for weight management in the EU.
•The EC also approved a Wegovy 7.2 mg injection in a single-dose pen, which demonstrated 21% weight loss in trials.
